

- HPV-RELATED DISEASES
- IMMUNO-ONCOLOGY
- INFECTIOUS DISEASES
- VARIOUS DISEASE TARGETS

REGISTRATION

INO-3107 *
RRP

PHASE 2

VGX-3100
Anal Dysplasia

INO-3112 **
Head & Neck Cancer

INO-5401 ***
Glioblastoma

PHASE 1

INO-5401
BRCA1/2 Mutation

INO-4201
Ebola Booster

INO-6172
HIV

INO-6160
HIV

DMAbs ****
Proof of concept target: COVID-19

PRECLINICAL

DMAbs
Various Targets

DPROTs
Various Targets

DLNPs
Various targets

OUT-LICENSED

PHASE 3

VGX-3100 *****
Cervical Dysplasia (HSIL)

INO-4800 *****
COVID-19

* INO-3107: Preparing BLA submission under accelerated approval program; FDA agreed to rolling submission timeline. Goal to complete submission by 2H25 with acceptance of file by FDA by YE25. The timing of regulatory submissions and clinical trial milestones are subject to change and additional discussions with regulators.

** INO-3112: Next study is expected to be a Phase 3 in combination with LOQTORZI®; signed supply agreement with Coherus for LOQTORZI in January 2024

*** INO-5401 Phase 1/2 trial conducted in combination with LIBTAYO® under collaboration agreement with Regeneron

**** DMAbs: Next-gen technology, first Phase 1 study is a proof-of-concept study using COVID -19 mAbs as a target to demonstrate capabilities of platform

***** VGX-3100 to ApolloBio for China

***** INO-4800 to Advaccine for China